VCs Facing Longer Timeframes, Higher Hurdles In Med Tech Investments
This article was originally published in The Gray Sheet
Medical technology start-ups are currently looking at relationships of up to seven years with their venture capital equity partners, up from four or five in the recent past, as the pace of exit opportunities through initial public offerings or merger and acquisition activities has slowed dramatically
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.